Research

Zacks Small Cap Analysis – UHAL: U-Haul Holding Firm Reviews 4Q and full-year FY2025 Outcomes. Revenues have been above expectations within the seasonally sluggish 4Q, however the backside line was impacted by rising depreciation expense in addition to by decrease resale values for retired vans. Additionally, an Annual Evaluation of FY2025. – Model Slux

by
Zacks Small Cap Analysis – UHAL: U-Haul Holding Firm Reviews 4Q and full-year FY2025 Outcomes. Revenues have been above expectations within the seasonally sluggish 4Q, however the backside line was impacted by rising depreciation expense in addition to by decrease resale values for retired vans. Additionally, an Annual Evaluation of FY2025. – Model Slux

By Steven Ralston, CFA NYSE:UHAL READ THE FULL UHAL RESEARCH REPORT EXECUTIVE SUMMARY U-Haul Holding Firm (NYSE: UHAL) reported 4Q and full-year FY2025 outcomes on Might 28th after the shut. Revenues have been above expectations within the seasonally slowest quarter, however the backside line was impacted by rising depreciation expense from the upper costs paid … Read more

Zacks Small Cap Analysis – TELO Continues Development of Important Trial Bulletins – Model Slux

by

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Prescribed drugs (NASDAQ:TELO) is a preclinical stage biopharmaceutical firm growing a product designed to reverse organic getting older and degenerative ailments. Beforehand reported preclinical exams have proven proof that Telomir-1, the corporate’s major remedy, can lengthen telomeres and preliminary animal testing illustrates the … Read more

Zacks Small Cap Analysis – GRCE: Progress Report – Model Slux

by
Zacks Small Cap Analysis – GRCE: Progress Report – Model Slux

By John Vandermosten, CFA NASDAQ:GRCE READ THE FULL GRCE RESEARCH REPORT Grace Therapeutics, Inc (NASDAQ:GRCE) will quickly submit its new drug software (NDA) to the FDA, which we anticipate within the subsequent few weeks. The corporate just lately held a pre-NDA assembly with the FDA and got here away feeling carefully aligned with the company … Read more

Zacks Small Cap Analysis – QSG F3Q25 Earnings Assessment: EPS Miss on Decrease Revenues/Working Revenue; Unlocking a New Progress Lever – Model Slux

by

By Michael Kim NASDAQ:QSG READ THE FULL QSG RESEARCH REPORT Pre-market open on 6/6/25, QuantaSing (NASDAQ:QSG) reported F3Q25 (Mar) earnings outcomes. On a GAAP foundation, QSG reported internet earnings of $5.7 million for F3Q25, or $0.10 per ADS. That mentioned, excluding share-based compensation bills, adjusted EPS got here in at $0.11, or beneath our estimate … Read more

Zacks Small Cap Analysis – EVAX: Grant Illustrates Perception in Know-how – Model Slux

by

By Brad Sorensen, CFA NASDAQ:EVAX READ THE FULL EVAX RESEARCH REPORT Evaxion (NASDAQ:EVAX) is a scientific stage firm that’s making AI helpful within the present atmosphere by utilizing the expertise to develop new cancer-fighting vaccines. The corporate notes that it has demonstrated that it could establish, by means of the corporate’s AI fashions, novel targets … Read more

x